Comparative Pharmacology
Head-to-head clinical analysis: EDURANT versus RESCRIPTOR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EDURANT versus RESCRIPTOR.
EDURANT vs RESCRIPTOR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Rilpivirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that binds to HIV-1 reverse transcriptase, causing conformational changes that inhibit enzyme activity and viral replication.
Non-nucleoside reverse transcriptase inhibitor (NNRTI) that binds directly to HIV-1 reverse transcriptase, causing conformational change and inhibiting RNA-dependent DNA polymerase activity.
25 mg orally once daily with a meal.
400 mg orally three times daily.
None Documented
None Documented
Terminal half-life 38 hours (range 25-57 h); supports once-daily dosing, steady state at ~7 days
Terminal elimination half-life is 2.5–4.5 hours in adults. This short half-life necessitates twice-daily dosing. In patients with hepatic impairment, half-life may be prolonged.
Renal (~25% unchanged) and fecal (~60% as metabolites); total recovery ~85%
Renal: 51% (unchanged drug) and 44% (glucuronide metabolite); biliary/fecal: <5%. Total recovery in urine is approximately 95%.
Category C
Category C
NNRTI Antiretroviral
NNRTI Antiretroviral